Krilogy Financial’s Corcept Therapeutics CORT Stock Holding History

Krilogy Financial’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$897K	Buy	7,404 +1,293	+21%	+$139K	0.02%	453
2026 Q2	$531K	Buy	+6,111	New	+$369K	0.02%	614
2018 Q4	–	Sell	-200	Closed	-$3K	–	237
2018 Q3	$3K	Buy	+200	New	+$2.8K	﹤0.01%	671
2018 Q2	–	Sell	-200	Closed	-$3K	–	248
2018 Q1	$3K	Buy	+200	New	+$3.71K	﹤0.01%	647

Other funds holding CORT

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Linden Thomas Advisory Services Charlotte, North Carolina $1.26B AUM 37.95% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Krilogy Financial's CORT Position: Q3 2026 in Review

Krilogy Financial increased its Corcept Therapeutics (CORT) stake by 21% in Q3 2026, buying an estimated $139K and bringing the position to 7,404 shares worth $897K. The position accounts for 0.02% of the portfolio, ranked #453.

Krilogy Financial first reported a position in CORT in Q1 2018 and has held it in 4 quarters since. 84 funds tracked by Wall St. Rank hold CORT as of Q3 2026.

Krilogy Financial held 7,404 shares of Corcept Therapeutics worth $897K as of Q3 2026.
Krilogy Financial bought 1,293 Corcept Therapeutics shares in Q3 2026, an estimated $139K.
Corcept Therapeutics made up 0.02% of Krilogy Financial's portfolio in Q3 2026, its #453 holding.
Krilogy Financial first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 4 quarters since.
84 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2026.

Based on Krilogy Financial's 13F filing for Q3 2026, filed 13 Oct 2026.